Stock Markets July 9, 2026 05:05 AM

J.P. Morgan Raises Wolters Kluwer to Overweight, Cites AI Momentum and Attractive Valuation

Analyst upgrades stock and lifts target to €87 as AI investments, acquisitions and platform strengths underpin a refreshed bullish thesis

By Ajmal Hussain
Share
Twitter Reddit Facebook LinkedIn

J.P. Morgan upgraded Wolters Kluwer to Overweight from Neutral and increased its price target to €87 from €73, citing what it views as compelling valuation and evidence that artificial intelligence will accelerate growth across the company’s core information-services businesses. Shares rose nearly 4% in Amsterdam after the call. The bank cut WACC assumptions for several divisions, lifted terminal growth expectations and flagged recent AI-focused acquisitions as proof the company is strengthening its competitive position.

J.P. Morgan Raises Wolters Kluwer to Overweight, Cites AI Momentum and Attractive Valuation
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • J.P. Morgan upgraded Wolters Kluwer to Overweight and raised its price target to €87 from €73, driving a near 4% share rise in Amsterdam - impacts information services and enterprise software sectors.
  • The bank reduced WACC assumptions for Legal, Tax and Financial & Corporate Compliance divisions and boosted the terminal growth rate, underpinning a higher target that still implies a 2027 P/E multiple discount to peer Pearson - relevant to valuation-focused investors and equity analysts.
  • Recent acquisitions of AI-focused businesses (Libra for ~€30 million and Brightflag for ~€425 million in June 2025) are seen as accelerating Wolters Kluwer’s AI roadmap and strengthening its position in mission-critical workflow platforms - important for legal tech and compliance software markets.

J.P. Morgan has upgraded Wolters Kluwer to Overweight from Neutral and raised its price target to €87 from €73, saying the move reflects growing conviction that the Dutch information services group is poised to benefit from accelerating AI adoption across its business lines.

The recommendation sent Wolters Kluwer shares up almost 4% in Amsterdam trading following the upgrade.

Analyst Daniel Kerven told clients the upgrade stems from a view that recent investments, corporate acquisitions and the rollout of new AI-enabled products have enhanced the company’s defensive advantage - what he describes as an "AI moat." Rather than depending solely on proprietary content, Kerven emphasized that Wolters Kluwer’s edge is rooted in ownership of mission-critical workflow platforms and systems of record. In this setup, AI is expected to augment long-standing data, regulatory and workflow processes rather than displace them.

On the valuation side, J.P. Morgan lowered its weighted average cost of capital assumptions for Wolters Kluwer’s Legal, Tax and Financial & Corporate Compliance divisions and raised the terminal growth rate used in its model. Those changes, together with a modest currency tailwind, were the primary drivers behind the higher price target. The €87 target equates to a 2027 price-to-earnings multiple of 12.9 times, which the bank notes remains about a 20% discount to peer Pearson.

Kerven observed the stock is trading at roughly 9 times 2027 estimated earnings, representing a 40% discount to RELX and a 60% discount to U.S. peers, according to his analysis. He also flagged potential private equity interest, outlining an illustrative leveraged buyout scenario that could produce a base-case internal rate of return of 17% assuming a 30% takeover premium, with an upside to 23% if select assets such as the Tax division were sold at premium multiples.

The analyst pointed to two recent deals as evidence the company has accelerated its AI roadmap. Wolters Kluwer acquired German legal AI startup Libra in January for roughly €30 million, and in June 2025 it bought Brightflag, an AI-driven legal spend management platform, for about €425 million. Kerven said those transactions lowered the risk that Wolters Kluwer would be slow to respond to AI-driven disruption and opportunity.

Despite the more constructive stance on large parts of the business, J.P. Morgan retains a negative view on the company’s UpToDate clinical information unit. The bank assumes UpToDate’s organic growth will turn negative within five years as it faces competition from AI-native rivals, but it still values the unit at roughly €2.6 billion and attributes that valuation to expected years of positive cash flow.

Kerven described the move as likely the firm’s first substantive upgrade of Wolters Kluwer in 18 months, adding that consensus price targets are only now beginning to adjust to risks that have already been reflected in the share price. The stock has fallen more than 55% over the past 12 months, a decline he used as context for why consensus estimates had lagged the deterioration in investor sentiment.


Note: The article reflects J.P. Morgan’s revised assumptions and Kerven’s analysis as presented to clients, including the specific deal values and valuation metrics cited above.

Risks

  • J.P. Morgan remains negative on Wolters Kluwer’s UpToDate clinical information unit, forecasting organic growth could turn negative within five years amid competition from AI-native rivals - a risk for the healthcare information sector.
  • The share price has declined by more than 55% over the past 12 months, indicating significant market skepticism and potential downside if the company’s AI initiatives fail to produce expected results - relevant to equity investors and risk managers.
  • Potential private equity interest is speculative in outcome; while J.P. Morgan models an illustrative LBO with a base-case IRR of 17% assuming a 30% takeover premium, such transactions and asset sales (for example, of the Tax division) carry execution and market risks - affecting M&A and financial sponsors activity.

More from Stock Markets

AI Windfalls and SpaceX Listings Drive Surge in Demand for Private Aircraft Jul 9, 2026 BridgeBio Shares Jump After Rival Phase III Trial Fails, Reinforcing Attruby’s Market Position Jul 9, 2026 Nokia Defense and NestAI Move to Deliver First Operational AI-Enabled Defense Capabilities Jul 9, 2026 PepsiCo Tops Q2 Revenue Estimates While Warning of Consumer Budget Strain Jul 9, 2026 Shares of Alnylam and BridgeBio Rally After Rival’s Late-Stage Heart Drug Misses Primary Goals Jul 9, 2026